Today represents a milestone for Truffle Capital. Our portfolio company Neovacs successfully completed an IPO on NYSE Euronext Paris. This is significant because it represents Truffle’s first IPO in the biotech sector and portends favorably for the public markets.

Neovacs is a biotechnology company focused on an active immunotherapy technology platform with applications in autoimmune diseases and other chronic conditions.

Read the announcement.

Congratulations to the Neovacs management team and my biotech colleagues !